Assessment of Real-life Patient Handling Experience of BI 695501 Administered Subcutaneously With an Autoinjector in Patients With Rheumatoid Arthritis: an Open-label, Interventional Clinical Trial Followed by an Extension Phase of BI 695501 Administered With a Prefilled Syringe
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 25 Jul 2017 Status changed from active, no longer recruiting to completed.
- 27 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 01 Jun 2016 Planned End Date changed from 1 Jul 2017 to 1 Jun 2017.